Training should be the first step toward an antifungal stewardship program

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 33, Issue 4, 2015, Pages 221-227

  Valerio, Maricela ^a,b   Muñoz, Patricia ^a,b,c,d   Rodríguez González, Carmen ^a,b   Sanjurjo, María ^a,b   Guinea, Jesús ^a,b   Bouza, Emilio ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

Antifungal stewardship; Antifungal use; Candins; Fluconazole; Invasive aspergillosis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GALACTOMANNAN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; DIAGNOSTIC VALUE; FEMALE; FUNGAL COLONIZATION; HUMAN; INTENSIVE CARE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; PHYSICIAN; PRACTICE GUIDELINE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT INDICATION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL STEWARDSHIP PROGRAM; CANDIDEMIA; CANDIDIASIS; CONTINUING EDUCATION; DRUG USE; EDUCATION PROGRAM; HEALTH CARE; HOSPITAL DEPARTMENT; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MYCOSIS; PEDIATRIC WARD; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; PROPHYLAXIS; SURGICAL WARD; CANDIDIASIS, INVASIVE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DRUG UTILIZATION; EDUCATION; HEALTH CARE SURVEY; HETEROZYGOTE; INAPPROPRIATE PRESCRIBING; INFECTIOUS DISEASE MEDICINE; INVASIVE FUNGAL INFECTIONS; PREVENTION AND CONTROL; STATISTICS AND NUMERICAL DATA;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; CARRIER STATE; DIAGNOSIS, DIFFERENTIAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EDUCATION, MEDICAL, CONTINUING; HEALTH CARE SURVEYS; HUMANS; INAPPROPRIATE PRESCRIBING; INFECTIOUS DISEASE MEDICINE; INVASIVE FUNGAL INFECTIONS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; SURVEYS AND QUESTIONNAIRES;

EID: 84926251027     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2014.04.016     Document Type: Article

References (34)

1. A. Apisarnthanarak, A. Yatrasert, and L.M. Mundy Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center Infect Control Hosp Epidemiol 31 2010 722 727
2. A. Sutepvarnon, A. Apisarnthanarak, B. Camins, K. Mondy, and V.J. Fraser Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study Infect Control Hosp Epidemiol 29 2008 370 373
3. F. Gutierrez, P.G. Wall, and J. Cohen An audit of the use of antifungal agents J Antimicrob Chemother 37 1996 175 185
4. E. Azoulay, H. Dupont, A. Tabah, O. Lortholary, J.P. Stahl, and A. Francais Systemic antifungal therapy in critically ill patients without invasive fungal infection Crit Care Med 40 2012 813 822
5. T.H. Dellit, R.C. Owens, J.E. McGowan Jr.; D.N. Gerding, R.A. Weinstein, and J.P. Burke Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 44 2007 159 177
6. P.G. Pappas, C.A. Kauffman, and D. Andes Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
7. T.J. Walsh, E.J. Anaissie, and D.W. Denning Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360
8. P. Eggimann, P. Francioli, J. Bille, R. Schneider, M.M. Wu, and G. Chapuis Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients Crit Care Med 27 1999 1066 1072
9. J. Garbino, D.P. Lew, J.A. Romand, S. Hugonnet, R. Auckenthaler, and D. Pittet Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination Intensive Care Med 28 2002 1708 1717
10. S. Jacobs, D.A. Price Evans, M. Tariq, and N.F. Al Omar Fluconazole improves survival in septic shock: a randomized double-blind prospective study Crit Care Med 31 2003 1938 1946
11. R.K. Pelz, C.W. Hendrix, S.M. Swoboda, M. Diener-West, W.G. Merz, and J. Hammond Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients Ann Surg 233 2001 542 548
12. A.F. Shorr, K. Chung, W.L. Jackson, P.E. Waterman, and M.H. Kollef Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Crit Care Med 33 2005 1928 1935
13. E.G. Playford, A.C. Webster, T.C. Sorrell, and J.C. Craig Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials J Antimicrob Chemother 57 2006 628 638
14. E.G. Playford, P. Eggimann, and T. Calandra Antifungals in the ICU Curr Opin Infect Dis 21 2008 610 619
15. M.A. Slavin, T.C. Sorrell, D. Marriott, K.A. Thursky, Q. Nguyen, and D.H. Ellis Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death J Antimicrob Chemother 65 2010 1042 1051
16. J. Garnacho-Montero, A. Diaz-Martin, E. Garcia-Cabrera, M. Ruiz Perez de Pipaon, C. Hernandez-Caballero, and J. Aznar Martin Risk factors for fluconazole-resistant candidemia Antimicrob Agents Chemother 54 2010 3149 3154
17. L. Ostrosky-Zeichner, C. Sable, J. Sobel, B.D. Alexander, G. Donowitz, and V. Kan Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting Eur J Clin Microbiol Infect Dis 26 2007 271 276
18. L.A. Mermel, M. Allon, E. Bouza, D.E. Craven, P. Flynn, and N.P. O'Grady Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America Clin Infect Dis 49 2009 1 45
19. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
20. M. Morrell, V.J. Fraser, and M.H. Kollef Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 2005 3640 3645
21. A.M. Tortorano, C. Kibbler, J. Peman, H. Bernhardt, L. Klingspor, and R. Grillot Candidaemia in Europe: epidemiology and resistance Int J Antimicrob Agents 27 2006 359 366
22. J. Guinea, T. Pelaez, M. Rodriguez-Creixems, M. Torres-Narbona, P. Munoz, and L. Alcala Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents? Med Mycol 47 2009 515 520
23. P. Munoz, C.P. Fernandez-Turegano, L. Alcala, M. Rodriguez-Creixems, T. Pelaez, and E. Bouza Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole Diagn Microbiol Infect Dis 44 2002 163 167
24. C.J. Clancy, V.L. Yu, A.J. Morris, D.R. Snydman, M.H. Nguyen, and M.I.C. Fluconazole and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia Antimicrob Agents Chemother 49 2005 3171 3177
25. M.P. Pai, R.S. Turpin, and K.W. Garey Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia Antimicrob Agents Chemother 51 2007 35 39
26. J.W. Baddley, M. Patel, S.M. Bhavnani, S.A. Moser, and D.R. Andes Association of fluconazole pharmacodynamics with mortality in patients with candidemia Antimicrob Agents Chemother 52 2008 3022 3028
27. J.L. Rodriguez-Tudela, B. Almirante, and D. Rodriguez-Pardo Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia Antimicrob Agents Chemother 51 2007 3599 3604
28. M.A. Pfaller, D.J. Diekema, and D.J. Sheehan Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing Clin Microbiol Rev 19 2006 435 447
29. E. Bouza, J. Guinea, T. Pelaez, J. Perez-Molina, L. Alcala, and P. Munoz Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital J Clin Microbiol 43 2005 2075 2079
30. R. Herbrecht, D.W. Denning, and T.F. Patterson Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
31. T.J. Walsh, P. Pappas, and D.J. Winston Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
32. J.R. Perfect, K.A. Marr, and T.J. Walsh Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 2003 1122 1131
33. D.W. Denning, P. Ribaud, and N. Milpied Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 2002 563 571
34. J. Smith, and D. Andes Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations Ther Drug Monit 30 2008 167 172